NCT00757978
Completed
Phase 4
Phase 4 Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms in Patients Using Clozapine. A Randomized, Double-Blind, Placebo Controled Study
Overview
- Phase
- Phase 4
- Intervention
- placebo
- Conditions
- Schizophrenia
- Sponsor
- Hospital de Clinicas de Porto Alegre
- Enrollment
- 22
- Locations
- 1
- Primary Endpoint
- Score in Brief Psychiatric Raring Scale
- Status
- Completed
- Last Updated
- 17 years ago
Overview
Brief Summary
Memantine as an add-on therapy to clozapine may improve schizophrenia negative symptoms and cognitive functioning.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Under clozapine with negative symptoms
Exclusion Criteria
- •Pregnancy
- •Lactation
Arms & Interventions
1
Clozapine plus placebo
Intervention: placebo
2
Clozapine plus memantine
Intervention: memantine
Outcomes
Primary Outcomes
Score in Brief Psychiatric Raring Scale
Time Frame: baseline, 4 weeks, 8 weeks, 12 weeks
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Memantine as an adjunctive therapy to ongoing clozapine treatment: a proof-of-concept study and follow-up studyISRCTN14760638Mental Health Service Organisation North Holland North, Community Mental Health Division52
Completed
Phase 2
Memantine Augmentation of Targeted Cognitive Training in SchizophreniaSchizophreniaSchizoaffective DisorderNCT04857983University of California, San Diego62
Completed
Phase 2
Memantine Add-On Therapy to ClozapineNL-OMON39302GGZ NH52
Active, not recruiting
Not Applicable
Memantine as an adjunctive therapy to ongoing clozapine treatment: a proof-of-concept studyEUCTR2011-003466-33-NLMental Health Services North Holland North
Unknown
Phase 3
Amantadine as Adjunctive Therapy to Antipsychotics in SchizophreniaSchizophreniaNCT00999505Hospital de Clinicas de Porto Alegre40